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Erythropoietic protoporphyria (EPP; E80.0, ICD-10) is
an inherited disorder resulting from partially deficient
activity of ferrochelatase, the last enzyme in the heme
biosynthetic pathway (1). In EPP, protoporphyrin
accumulates in erythrocytes, bile, and skin, with pho-
toactivation of accumulated protoporphyrin causing
endothelial injury. Thus, the main symptom of EPP is
painful cutaneous photosensitivity. Diffuse edema of
the skin in sun-exposed areas may resemble angio-
neurotic edema; in most cases, however, burning and
itching initially occur without obvious skin damage.
Typically the disease becomes symptomatic before
the age of 2 years, but diagnosis is typically delayed
by 10 years (2), and late-onset cases have been rec-
ognized in hematological diseases (3). Severe and in
some cases fulminating liver disease occurs in 5% of
EPP patients, potentially requiring liver transplanta-
tion (4, 5). The disease has an autosomal pseudo-
dominant, and in some cases autosomal recessive
pattern of inheritance (6, 7), and a variety of muta-
tions have been found to cause EPP (8). The disorder
has only been clearly recognized since 1961 (9). Exact
data on the prevalence of EPP are not available: in the
United Kingdom 389 EPP cases were documented in
2006 (2), but substantially more cases must be
assumed.
An increased concentration of free protoporphyrin
in erythrocytes is the laboratory hallmark of EPP.
‘‘Free’’ protoporphyrin (protoporphyrin without any
central atom) is indeed the only heme pathway inter-
mediate that accumulates significantly in this disease.
Although a number of conditions such as iron-defi-
cient erythropoiesis, lead intoxication, and hemato-
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logical diseases can lead to increased erythrocyte
zinc protoporphyrin concentrations, significantly
increased free protoporphyrin concentrations are
assumed to be found exclusively in EPP. Slightly
increased levels of free protoporphyrin are observed
under conditions of zinc depletion and iron deficiency,
sometimes in sideroblastic anemia and other hema-
tological diseases, and in homozygous or compound
heterozygous porphyrias such as hepatoerythropoie-
tic porphyria, Doss porphyria (d-aminolevulinate
dehydratase-deficiency porphyria) and congenital
erythropoietic porphyria (Morbus Guenther). How-
ever, clinically relevant concentrations are never
attained in these cases.
Since EPP does not present with visible or charac-
teristic skin abnormalities in many cases (10), eryth-
rocyte protoporphyrin measurement is of essential
importance for primary diagnosis of EPP in children
and adolescents with avoidance behavior towards
sun exposure. In the follow-up of EPP patients, eryth-
rocyte protoporphyrin measurement can potentially
help (in addition to quantification of fecal protopor-
phyrin excretion and the isomeric ratio of copropor-
phyrin in urine) in early recognition of transition of
the disease to a fulminate phase, in which worsening
cholestasis leads to further accumulation of protopor-
phyrin in a vicious cycle (4, 5).
Quantification of free erythrocyte protoporphyrin
concentrations still represents an analytical challenge
and is performed in only a few specialized laborato-
ries. The first approach to laboratory diagnosis of EPP
was the demonstration of fluorescent red cells (‘‘fluo-
rocytes’’) in blood films viewed under ultraviolet light
(11). Several chromatographic methods for specific
quantification of erythrocyte free protoporphyrinwere
subsequently described (12, 13). In such assays, sam-
ple preparation with full-recovery analyte extraction
is delicate and the chromatographic separation of free
from zinc-chelated protoporphyrin is demanding.
Blood-based materials for calibration and quality
control of erythrocyte free protoporphyrin quantifica-
tion are not commercially available at present and no
proficiency testing schemes have been implemented.
Indeed, there are no data published on agreement
between free erythrocyte measurements performed
in different laboratories. We therefore decided to
organize an inter-laboratory survey study of free
erythrocyte protoporphyrin measurement. Data from
this survey will be important in achieving harmon-
ization of protoporphyrin measurement in the future.
For this survey, 30 mL of heparinized whole blood
was sampled from an EPP patient after informed con-
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sent and approval by the Institutional Review Board.
Erythrocytes were separated from the plasma by
centrifugation, and washed with saline. Aliquots of
the sample were prepared and lyophilized in light-
protected vials in an industrial setting (Chromsys-
tems, Munich, Germany).
We can now invite interested colleagues to request
an aliquot of this sample (michael.vogeser@med.uni-
muenchen.de) for free erythrocyte protoporphyrin
measurement at no cost. The resulting data will be
evaluated after anonymization. It is intended to create
a research group with the participants of this survey
and to submit the data from this pilot investigation
for potential publication in Clinical Chemistry and
Laboratory Medicine.
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